RVMDRevolution Medicines, Inc.Signing up patients
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Resected Pancreatic Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 500 (planned)
- Started
- Dec 15, 2025
- Main results expected
- May 10, 2029
- Fully finished
- Jul 10, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease-Free Survival (DFS) per Investigator
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07252232 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC